Interpace Diagnostics (NASDAQ: IDXG) reported Q2 EPS of ($0.07), $0.02 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $5.5 million versus the consensus estimate of $5.04 million.

For earnings history and earnings-related data on Interpace Diagnostics (IDXG) click here.